David Tonkin, MD
Interventional Pain Medicine · Springfield, MONPI 1760438642
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,483 of the $13,995 with a category attached, or 67.8%. 31 manufacturers reported payments, led by Biotronik NRO, Inc. at 29.0% of the total.
Across 378 payments — averaging $37.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik NRO, Inc.$4K
- Boston Scientific$4K
- Abbott$3K
- Medtronic$1K
- Nevro Corp.$789
- Collegium Pharmaceutical, Inc.$229
- plus $920 from 25 others
What the payments were for
- Travel & lodging$4,51232%
- Food & beverage$9,48368%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik NRO, Inc. | 92 | $4,056 |
| Boston Scientific | 71 | $4,026 |
| Abbott | 69 | $2,577 |
| Medtronic(2 entities) | 82 | $1,398 |
| Nevro Corp. | 10 | $789 |
| Collegium Pharmaceutical, Inc. | 14 | $229 |
| Indivior Inc. | 5 | $171 |
| Johnson & Johnson | 5 | $112 |
| Sanofi | 3 | $87 |
| Nalu Medical, Inc. | 1 | $72 |
| Saluda Medical Americas, Inc. | 2 | $71 |
| Coloplast | 1 | $54 |
| Si-bone, Inc. | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| MDD US Operations, LLC | 2 | $27 |
| Pfizer | 2 | $24 |
| Vertex | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $18 |
| Painteq LLC | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| AbbVie | 1 | $11 |
| Spinal Simplicity, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIOTRONIK$1,525
- PROCLAIM$1,448
- GENERAL - THERAPIES$1,035
- WaveWriter Alpha Prime 16$979
- Prospera$895
- Senza Spinal Cord Stimulation System$419
- GENERAL PAIN MANAGEMENT$278
- Omnia$252
- INTELLIS ADAPTIVESTIM$233
- SUBLOCADE$107
- INTELLIS$102
How this compares
$13,995 in reported general payments places this provider in the 80th percentile of 27 interventional pain medicine providers in Missouri.
See all interventional pain medicine providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 42 | $41,057 |
| Buprenorphine | 39 | $9,903 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 158 | $3,307 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 197 | $3,287 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $2,350 |
| Novolog FlexpenInsulin Aspart | 13 | $2,045 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 14 | $1,418 |
| Oxycodone Hcl | 48 | $714 |
| Tramadol Hcl ErTramadol Hcl | 15 | $524 |
| Metoprolol Succinate | 13 | $230 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $193 |
| Levothyroxine Sodium | 14 | $188 |
| Tramadol Hcl | 57 | $187 |
| Potassium Chloride | 12 | $181 |
| Hydromorphone Hcl | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $229 | $41,05742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 27 interventional pain medicine providers in Missouri.
Other interventional pain medicine in Springfield
- Wayne WallenderSpringfield$403
- Rebecca SandersJoplin$209K
- Ramis GheithBridgeton$73K
- Helen BlakeChesterfield$48K
- Andrew FrazierKansas City$32K
- Christian OliverBridgeton$18K
- Dwayne JonesKansas City$11K
- Bradford NobleColumbia$8K
- Calvin CajigalDes Peres$8K
- James NewtonColumbia$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.